---
title: "RPRX: Q2 2026 delivered double-digit Royalty Receipts growth and raised full-year guidance"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294957965.md"
description: "Q2 2026 saw 14% Royalty Receipts growth and 6% higher Portfolio Receipts, with strong performance in oncology and immunology. Full-year guidance was raised, and over $1 billion was deployed in new transactions, including a major royalty acquisition.Original document: Royalty Pharma plc [RPRX] SEC 8-K Current Report — Aug. 5 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-05T11:21:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294957965.md)
  - [en](https://longbridge.com/en/news/294957965.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294957965.md)
generator: "portal-rs"
---

# RPRX: Q2 2026 delivered double-digit Royalty Receipts growth and raised full-year guidance

Q2 2026 saw 14% Royalty Receipts growth and 6% higher Portfolio Receipts, with strong performance in oncology and immunology. Full-year guidance was raised, and over $1 billion was deployed in new transactions, including a major royalty acquisition.

Original document: Royalty Pharma plc \[RPRX\] SEC 8-K Current Report — Aug. 5 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [RPRX.US](https://longbridge.com/en/quote/RPRX.US.md)

## Related News & Research

- [If You Invested $1000 In Royalty Pharma Stock 10 Years Ago, You Would Have This Much Today](https://longbridge.com/en/news/296656460.md)
- [Is Royalty Pharma (RPRX) Undervalued On Its $100 Million Zealand Pharma Royalty Deal?](https://longbridge.com/en/news/296647266.md)
- [Royalty Pharma EVP and Chairman of Partnering Christopher Hite sells 100,000 shares for $6 million](https://longbridge.com/en/news/296396564.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)
- [Royalty Pharma CFO Terrance P. Coyne sells USD 645,248 in common shares](https://longbridge.com/en/news/296146007.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**